Phase I Study of Decitabine-Mediated Induction of Tumor Antigen and Tumor Suppressor Gene Expression in Patients With Unresectable Lung or Esophageal Cancer or Malignant Pleural Mesothelioma
(Summary Last Modified 03/2002)
PATIENT ABSTRACT:
RATIONALE:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE:
Phase I trial to study the effectiveness of decitabine in treating patients who have unresectable lung or esophageal cancer or malignant mesothelioma of the pleura.
ELIGIBILITY:
At least 18 years old
At least 30 days since biological therapy or chemotherapy
No previous decitabine
TREATMENT
Patients will receive a 3-day continuous infusion of decitabine every 5 weeks for up to four courses. Patients will be evaluated once a month for 2 months.
This abstract is intended to give a brief overview of this clinical trial. To help determine whether the trial is appropriate for an individual, selected major eligibility criteria are listed above. To obtain more details related to trial eligibility and the treatment plan, please see the Health Professional abstract of this clinical trial. For more information about clinical trials, please visit the NCI cancerTrials website at http://cancertrials.nci.nih.gov.
PROTOCOL IDS
NCI-99-C-0129, NCI-T99-0012
PARTICIPATING ORGANIZATIONS/STUDY CONTACTS
David S. Schrump, Chair Ph: 301-496-2127
Center for Cancer Research
STUDY CONTACTS
Maryland
Patient Recruitment, Ph: 1-888-NCI-1937
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Bethesda, Maryland, U.S.A.
** POSTED APRIL 30, 2002 **